Precision BioSciences Details HBV Trial Data, Initiates DMD Clinical Trial
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences provided detailed positive clinical data for its chronic hepatitis B program and initiated a new clinical trial for Duchenne muscular dystrophy.
Key Events · Product Development and Regulatory · DTIL
-
Detailed HBV Clinical Data
Liver biopsy data from the ELIMINATE-B study showed PBGENE-HBV directly eliminated cccDNA, leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts, reinforcing the mechanism of action.
-
DMD Clinical Trial Commenced
The FUNCTION-DMD clinical trial for Duchenne muscular dystrophy has commenced with the activation of a second clinical site, targeting initial safety data by year-end 2026.
-
Next Program Updates
The company is targeting year-end 2026 for the next program updates for both the PBGENE-HBV and FUNCTION-DMD clinical trials.
Analysis · DTIL · Life Sciences
This filing provides crucial scientific validation for Precision BioSciences' lead gene editing program, PBGENE-HBV, by detailing liver biopsy data showing direct cccDNA elimination and a 1-log reduction in transcripts. Simultaneously, the company has commenced its FUNCTION-DMD clinical trial for Duchenne muscular dystrophy, expanding its clinical pipeline and targeting initial safety data by year-end 2026. These updates reinforce the company's clinical progress and pipeline development.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $7.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.8M. The 52-week trading range was $3.53 to $8.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.